Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07511582

PHASE2

Corticosteroids in Hyperinflammatory Phenotype of Critical Illness

Sponsor: Bin Du

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn whether methylprednisolone improves outcomes in critically ill patients with a hyperinflammatory phenotype. It will also evaluate the safety of methylprednisolone at different doses. The main questions it aims to answer are: * Does methylprednisolone improve organ function compared with placebo? * Does methylprednisolone reduce the risk of mortality within 30 days? Researchers will compare high-dose methylprednisolone (160mg/d), low-dose methylprednisolone (80mg/d), and placebo (normal saline) to evaluate effectiveness and safety. Participants will: * Receive high-dose methylprednisolone, low-dose methylprednisolone, or placebo every 12 hours for the first 3 days * Be reassessed on Day 4 based on their inflammatory status If the hyperinflammatory phenotype persists, the treatment dose will be reduced by half and continued until Day 7 or ICU discharge, whichever occurs first If the patient transitions to a hypoinflammatory phenotype, the study treatment will be discontinued * Be monitored daily in the intensive care unit for organ function, inflammatory status, and need for organ support * Be followed for up to 30 days after randomization to assess survival and recovery

Official title: Efficacy, Safety, and Tolerability of Methylprednisolone in Critically Ill Patients With the Hyperinflammatory Phenotype: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2026-04-01

Completion Date

2028-04-01

Last Updated

2026-04-09

Healthy Volunteers

Conditions

Sepsis Acute Respiratory Distress Syndrome

Interventions

DRUG

Methylprednisolone (MP)

Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

DRUG

Methylprednisolone (MP)

Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

DRUG

Placebo

Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

Inclusion Criteria: Participants must meet all of the following criteria: 1. Age ≥18 years. 2. Diagnosis of acute respiratory distress syndrome (ARDS) or sepsis. ARDS will be defined according to standard criteria: 1. acute onset within 1 week of a known clinical insult or new/worsening respiratory symptoms; 2. bilateral pulmonary opacities on chest imaging (X-ray or CT) or bilateral B-lines and/or consolidation on lung ultrasound, not fully explained by effusion, atelectasis, or nodules; 3. respiratory failure not fully explained by cardiac failure or fluid overload; 4. hypoxemia defined as PaO₂/FiO₂ ≤300 mmHg or SpO₂/FiO₂ ≤315 (with SpO₂ ≤97%) under a minimum positive end-expiratory pressure (PEEP) of 5 cmH₂O. Sepsis will be defined according to the Sepsis-3 criteria as suspected or confirmed infection with an acute increase in SOFA score ≥2 points, assuming a baseline SOFA score of 0 in patients without known prior organ dysfunction. Sepsis-associated ARDS will be defined as ARDS occurring in patients with sepsis. 3\. Receiving invasive mechanical ventilation. 4. Admission to the intensive care unit (ICU). 5. Hyperinflammatory phenotype, defined as a predicted probability ≥0.5 using a validated AI clinical classifier based on clinical data. 6\. Randomization within 72 hours of ARDS or sepsis onset. 7. Provision of written informed consent by the patient or their legally authorized representative. Exclusion Criteria: Participants meeting any of the following criteria will be excluded: 1. Requirement for high-dose vasopressor support, defined as norepinephrine ≥0.5 μg/kg/min or epinephrine ≥0.25 μg/kg/min. 2. Post-cardiac surgery patients (e.g., coronary artery bypass grafting or valve replacement). 3. Conditions requiring systemic corticosteroid therapy exceeding 1 mg/kg methylprednisolone or an equivalent dose (e.g., acute asthma exacerbation, acute exacerbation of chronic obstructive pulmonary disease, or autoimmune diseases). 4. Long-term systemic corticosteroid use within the past 6 months. 5. Pregnancy or lactation. 6. Brain death. 7. Advanced malignancy or other end-stage disease with an expected survival of less than 6 months, or anticipated death within 24 hours. 8. Known hypersensitivity to methylprednisolone, including but not limited to urticaria, eczema, angioedema, bronchospasm, or anaphylaxis. 9. History of solid organ transplantation or allogeneic hematopoietic stem cell transplantation. 10. Active life-threatening fungal infection or tuberculosis. 11. Neuromuscular disorders affecting spontaneous respiration. 12. Severe inherited or acquired immunodeficiency (e.g., human immunodeficiency virus infection, chronic granulomatous disease, or severe combined immunodeficiency). 13. Do-not-resuscitate (DNR) orders or withdrawal of life-sustaining treatment. 14. Concurrent participation in another interventional clinical trial. 15. Any other condition that, in the opinion of the treating physician or investigator, would make participation in the study inappropriate.

Locations (1)

Peking Union Medical College Hospital

Beijing, China

Clinical Research Directory

Corticosteroids in Hyperinflammatory Phenotype of Critical Illness

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (1)